<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02951416</url>
  </required_header>
  <id_info>
    <org_study_id>EurIPFreg_150609</org_study_id>
    <nct_id>NCT02951416</nct_id>
  </id_info>
  <brief_title>Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank</brief_title>
  <acronym>eurIPFreg</acronym>
  <official_title>The European IPF Registry - an Internet-based, Pan-European Registry Linked to the European IPF Biobank (eurIPFbank)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andreas Guenther</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Born out of the European Union 7th Framework Programme funded project European IPF Network
      (eurIPFnet), the European IPF Registry (eurIPFreg) has become Europe's leading database of
      longitudinal data from IPF patients, including control groups of patients with other lung
      diseases. The registry was initiated with the intention of creating a permanent and
      continuously growing record of well defined data on IPF in Europe, in order to increase the
      chances of finding better treatment options for this devastating disease.

      Clinical colleagues who would like to actively participate (both in terms of patient
      recruitment and data analysis) are invited to contact us
      (http://www.pulmonary-fibrosis.net/).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The group's work aims to foster research on Idiopathic Pulmonary Fibrosis (IPF), the most
      aggressive form of an Idiopathic Interstitial Pneumonia (IIP). Within the eurIPFreg we, the
      eurIPFreg steering committee and a growing number of external site investigators, aim to
      describe the natural course of IPF and other IIPs, to identify risk factors that are
      associated with the evolution of the disease and to sample biomaterials that may serve as
      underlying basis for translational research activities.

      IPF and non-specific interstitial pneumonia (NSIP), as well as the other entities of IIPs
      (cryptogenic organizing pneumonia, COP; desquamative interstitial pneumonia, DIP; respiratory
      bronchiolitis interstitial lung disease, RB-ILD; lymphoid interstitial pneumonia, LIP; acute
      interstitial pneumonia, AIP) are frequently progressive, fibroproliferative diseases of
      unknown etiology, affecting the lung parenchyma. Patients with IPF have the most devastating
      prognosis within the group of IIPs, with a median survival rate of 2-3 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">January 2040</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>60 Months</target_duration>
  <primary_outcome>
    <measure>clinical course of patients with Interstitial Lung Diseases (ILD)</measure>
    <time_frame>5 years</time_frame>
    <description>change of lung function parameter such as forced vital capacity (FVC), diffusing lung capacity (DLCO) over time mortality symptoms (reported in patients questionnaires)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comorbidities of patients with ILD</measure>
    <time_frame>5 years</time_frame>
    <description>reported in patients and physicians questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections in lung function of patients with ILD</measure>
    <time_frame>5 years</time_frame>
    <description>reported in patients and physicians questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of patients with ILD</measure>
    <time_frame>5 years</time_frame>
    <description>reported in patients and physicians questionnaires, EQ5D (European quality of life 5-dimensions) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care utilization of patients with ILD</measure>
    <time_frame>5 years</time_frame>
    <description>reported in patients questionnaires</description>
  </secondary_outcome>
  <number_of_groups>15</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <condition>Idiopathic Interstitial Pneumonia</condition>
  <condition>Interstitial Lung Diseases</condition>
  <condition>Diffuse Parenchymal Lung Diseases</condition>
  <arm_group>
    <arm_group_label>Idiopathic Pulmonary Fibrosis (IPF)</arm_group_label>
    <description>IPF diagnosis according to the guidelines of 2011 (AJRCCM 2011; 183:788). For patients diagnosed prior to 2011, the criteria of the consensus statement 2000 apply (AJRCCM 2000;161:646).
Patient registry (observation and biomaterial sampling).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-specific interstitial pneumonia</arm_group_label>
    <description>Non-specific interstitial pneumonia (NSIP) based on the histopathological demonstration of an NSIP pattern.
Patient registry (observation and biomaterial sampling).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryptogenic organising pneumonia (COP)</arm_group_label>
    <description>COP characterised histologically by an organising pneumonia with intraluminal organising fibrosis in the alveolar ducts and alveolar spaces.
Patient registry (observation and biomaterial sampling).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute interstitial pneumonia (AIP)</arm_group_label>
    <description>Histological pattern of diffuse alveolar damage (DAD), characterised by hyaline membranes, alveolar oedema and a marked interstitial and alveolar inflammatory reaction.
Patient registry (observation and biomaterial sampling).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lymphoid interstitial pneumonia (LIP)</arm_group_label>
    <description>Histological pattern of LIP primary or secondary (e.g. rheumatoid arthritis, Sj√∂gren's syndrome, pernicious anaemia, chronic active hepatitis, systemic lupus erythematosus (SLE), primary biliary cirrhosis, myasthenia gravis, severe immune deficiency syndromes (AIDS)).
Patient registry (observation and biomaterial sampling).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>respiratory bronchiolitis-ILD (RB-ILD)</arm_group_label>
    <description>Histological pattern of RB-ILD or typical clinical and radiological findings. Patient registry (observation and biomaterial sampling).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desquamative Interstitial Pneumonia</arm_group_label>
    <description>Histological pattern of Desquamative Interstitial Pneumonia (DIP). The picture is similar to RB-ILD, but the distribution pattern is much more homogeneous and does not even have the bronchiolocentric distribution.
Patient registry (observation and biomaterial sampling).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypersensitivity Pneumonitis</arm_group_label>
    <description>Hypersensitivity Pneumonitis (HP) characterized by exposure to inhaled organic antigens and development of antibodies. Typical clinical and radiological findings, lymphocytosis in bronchoalveolar lavage (BAL) or histology showing HP granulomas.
Patient registry (observation and biomaterial sampling).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarcoidosis</arm_group_label>
    <description>Histological pattern with sarcoid granulomas or typical clinical and radiological findings with a lymphocytosis in BAL.
Patient registry (observation and biomaterial sampling).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lung Cancer</arm_group_label>
    <description>Histological confirmation of Lung Cancer. Patients will be included as control group.
Patient registry (observation and biomaterial sampling).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Obstructive Pulmonary Disease</arm_group_label>
    <description>Obstructive spirometry and physical history suggesting Chronic Obstructive Pulmonary Disease (COPD). Patients will be included as control group.
Patient registry (observation and biomaterial sampling).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary Hypertension</arm_group_label>
    <description>Pulmonary Hypertension (PH) diagnosed through right heart catheterisation. Patients will be included as control group.
Patient registry (observation and biomaterial sampling).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sleep Apnea</arm_group_label>
    <description>Sleep Apnea diagnosed by polysomnography. Patients will be included as control group.
Patient registry (observation and biomaterial sampling).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthma</arm_group_label>
    <description>Asthma diagnosed by positive bronchoprovocation test and typical history or bronchoreversibility in the lung function measurement or through peak flow measurement. Patients will be included as control group.
Patient registry (observation and biomaterial sampling).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control/Health Individuals</arm_group_label>
    <description>Healthy volunteers not suffering from any lung disease as control group. Patient registry (observation and biomaterial sampling).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>patient registry (observation and biomaterial sampling)</intervention_name>
    <description>data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected</description>
    <arm_group_label>Idiopathic Pulmonary Fibrosis (IPF)</arm_group_label>
    <arm_group_label>Non-specific interstitial pneumonia</arm_group_label>
    <arm_group_label>Cryptogenic organising pneumonia (COP)</arm_group_label>
    <arm_group_label>Acute interstitial pneumonia (AIP)</arm_group_label>
    <arm_group_label>Lymphoid interstitial pneumonia (LIP)</arm_group_label>
    <arm_group_label>respiratory bronchiolitis-ILD (RB-ILD)</arm_group_label>
    <arm_group_label>Desquamative Interstitial Pneumonia</arm_group_label>
    <arm_group_label>Hypersensitivity Pneumonitis</arm_group_label>
    <arm_group_label>Sarcoidosis</arm_group_label>
    <arm_group_label>Lung Cancer</arm_group_label>
    <arm_group_label>Chronic Obstructive Pulmonary Disease</arm_group_label>
    <arm_group_label>Pulmonary Hypertension</arm_group_label>
    <arm_group_label>Sleep Apnea</arm_group_label>
    <arm_group_label>Asthma</arm_group_label>
    <arm_group_label>Control/Health Individuals</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EDTA blood, Plasma, Serum, GenePAX blood, BALF, BALCP, lung tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Interstitial Lung Diseases
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent signed

        Exclusion Criteria:

          -  No informed consent signed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andreas Guenther, MD</last_name>
    <phone>+49 64198542502</phone>
    <email>andreas.guenther@innere.med.uni-giessen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jasmin Wagner, MD</last_name>
    <phone>+49 64198542502</phone>
    <email>jasmin.wagner@innere.med.uni-giessen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Universit√§t Wien</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Klepetko</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Bonniaud</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Crestani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Andreas Guenther</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Guenther, MD</last_name>
      <phone>64198542502</phone>
      <phone_ext>502</phone_ext>
      <email>andreas.guenther@innere.med.uni-giessen.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Guenther, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel von der Beck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fotios Drakopanagiotakis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lungenfachklinik Waldhof Elgershausen</name>
      <address>
        <city>Greifenstein</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Guenther, MD</last_name>
      <phone>+49 6449 927</phone>
      <phone_ext>262</phone_ext>
    </contact>
    <investigator>
      <last_name>Andreas Guenther, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Loeh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universit√† degli Studi di Catania</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Vancheri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atholl Wells</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.pulmonary-fibrosis.net/</url>
    <description>European IPF Registry website</description>
  </link>
  <reference>
    <citation>Guenther A; European IPF Network. The European IPF Network: towards better care for a dreadful disease. Eur Respir J. 2011 Apr;37(4):747-8. doi: 10.1183/09031936.00012111.</citation>
    <PMID>21454892</PMID>
  </reference>
  <reference>
    <citation>Loeh B, Drakopanagiotakis F, Bandelli GP, von der Beck D, Tello S, Cordani E, Rizza E, Barrocu L, Markart P, Seeger W, Guenther A, Albera C. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2015 Jan 1;191(1):110-3. doi: 10.1164/rccm.201406-1106LE.</citation>
    <PMID>25551350</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Giessen</investigator_affiliation>
    <investigator_full_name>Andreas Guenther</investigator_full_name>
    <investigator_title>Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

